Safety assessment of inhaled xylitol in mice and healthy volunteers

Lakshmi Durairaj, Janice Launspach, Janet L Watt, Thomas R Businga, Joel N Kline, Peter S Thorne, Joseph Zabner, Lakshmi Durairaj, Janice Launspach, Janet L Watt, Thomas R Businga, Joel N Kline, Peter S Thorne, Joseph Zabner

Abstract

Background: Xylitol is a 5-carbon sugar that can lower the airway surface salt concentration, thus enhancing innate immunity. We tested the safety and tolerability of aerosolized iso-osmotic xylitol in mice and human volunteers.

Methods: This was a prospective cohort study of C57Bl/6 mice in an animal laboratory and healthy human volunteers at the clinical research center of a university hospital. Mice underwent a baseline methacholine challenge, exposure to either aerosolized saline or xylitol (5% solution) for 150 minutes and then a follow-up methacholine challenge. The saline and xylitol exposures were repeated after eosinophilic airway inflammation was induced by sensitization and inhalational challenge to ovalbumin. Normal human volunteers underwent exposures to aerosolized saline (10 ml) and xylitol, with spirometry performed at baseline and after inhalation of 1, 5, and 10 ml. Serum osmolarity and electrolytes were measured at baseline and after the last exposure. A respiratory symptom questionnaire was administered at baseline, after the last exposure, and five days after exposure. In another group of normal volunteers, bronchoalveolar lavage (BAL) was done 20 minutes and 3 hours after aerosolized xylitol exposure for levels of inflammatory markers.

Results: In naive mice, methacholine responsiveness was unchanged after exposures to xylitol compared to inhaled saline (p = 0.49). There was no significant increase in Penh in antigen-challenged mice after xylitol exposure (p = 0.38). There was no change in airway cellular response after xylitol exposure in naive and antigen-challenged mice. In normal volunteers, there was no change in FEV1 after xylitol exposures compared with baseline as well as normal saline exposure (p = 0.19). Safety laboratory values were also unchanged. The only adverse effect reported was stuffy nose by half of the subjects during the 10 ml xylitol exposure, which promptly resolved after exposure completion. BAL cytokine levels were below the detection limits after xylitol exposure in normal volunteers.

Conclusions: Inhalation of aerosolized iso-osmotic xylitol was well-tolerated by naive and atopic mice, and by healthy human volunteers.

Figures

Figure 1
Figure 1
Effect of saline and xylitol exposure on methacholine responsiveness in naïve mice (n = 6/group). Panel A reflects methacholine responsiveness before and after saline exposure. Panel B reflects methacholine responsiveness before and after xylitol exposure. Error bars = SD. P-values of all comparisons are non-significant.
Figure 2
Figure 2
Effect of saline vs. xylitol exposure on Penh of naïve C57BL/6 mice (n = 6). The figure shows mean Penh values for mice exposed to saline (circles) and xylitol (squares). Errors bars = SD. p = 0.21.
Figure 3
Figure 3
Invasive airway resistance measurement in response to methacholine challenge in naïve and ova-challenged C57BL/6 mice (n = 2/group) using Flexivent system. The figure shows mean airway resistance for naïve mice (squares) ova-challenged mice (triangles).
Figure 4
Figure 4
Effect of exposure to nebulized saline and xylitol on spirometry in normal volunteers (n = 10). The figure shows mean FEV1 (% predicted) at baseline, after exposure to saline (10 ml), and xylitol (1, 5, and 10 ml). Errors bars = SD. p = 0.19.

References

    1. Travis SM, Singh PK, Welsh MJ. Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol. 2001;13:89–95. doi: 10.1016/S0952-7915(00)00187-4.
    1. Lehrer RI, Ganz T. Antimicrobial peptides in mammalian and insect host defense. Curr Opin Immunol. 1999;11:23–27. doi: 10.1016/S0952-7915(99)80005-3.
    1. Huttner KM, Bevins CL. Antimicrobial peptides as mediators of epithelial host defense. Pediatr Res. 1999;45:785–794.
    1. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest. 1999;103:303–307.
    1. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic inlung that is inactivated in cystic fibrosis. Cell. 1997;88:553–560. doi: 10.1016/S0092-8674(00)81895-4.
    1. Bals R, Wang X, Wu Z, Freemann T, Bafna V, Zasloff M, Wilson JM. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest. 1998;102:874–880.
    1. Travis SM, Conway BA, Zabner J, Smith JJ, Anderson NN, Singh PK, Greenberg EP, Welsh MJ. Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol. 1999;20:872–879.
    1. Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, Tack BF, McCray PB. Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A. 1999;95:14961–14966. doi: 10.1073/pnas.95.25.14961.
    1. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996;85:229–236. doi: 10.1016/S0092-8674(00)81099-5.
    1. Folkesson HG, Matthay MA, Frigeri A, Verkman AS. Transepithelial water permeability in microperfused distal airways. Evidence for channel-mediated water transport. J Clin Invest. 1996;97:664–671.
    1. Zabner J, Smith JJ, Karp PH, Widdicombe JH, Welsh MJ. Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol Cell. 1998;2:397–403. doi: 10.1016/S1097-2765(00)80284-1.
    1. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95:1005–1015. doi: 10.1016/S0092-8674(00)81724-9.
    1. Zabner J, Seiler M, Launspach J, Karp PH, Kearney WR, Look DC, Smith JJ, Welsh MJ. The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. Proc Natl Acad Sci U S A. 2000;97:11614–11619. doi: 10.1073/pnas.97.21.11614.
    1. Makinen KK, Bennett CA, Hujoel PP, Isokangas PJ, Isotupa KP, Pape H. R. Jr., Makinen PL. Xylitol chewing gums and caries rates: a 40-month cohort study. J Dent Res. 1995;74:1904–1913.
    1. Soderling E, Makinen KK, Chen CY, Pape H. R. Jr., Loesche W, Makinen PL. Effect of sorbitol, xylitol, and xylitol/sorbitol chewing gums on dental plaque. Caries Res. 1989;23:378–384.
    1. Makinen KK. Long-term tolerance of healthy human subjects to high amounts of xylitol and fructose: general and biochemical findings. Int Z Vitam Ernahrungsforsch Beih. 1976;15:92–104.
    1. Uhari M, Kontiokari T, Koskela M, Niemela M. Xylitol chewing gum in prevention of actue otitus media: double blind randomised trial. BMJ. 1996;313:1180–1184.
    1. Daviskas E, Anderson SD, Brannan JD, Chan HK, Eberl S, Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J. 1997;10:2449–2454. doi: 10.1183/09031936.97.10112449.
    1. Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med. 1996;153:1503–1509.
    1. Pavia D, Thomson ML, Clarke SW. Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am Rev Respir Dis. 1978;117:199–203.
    1. Shibuya Y, Wills PJ, Kitamura S. The effects of lactose on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Eur Respir J. 1997;10:321S.
    1. Daviskas E, Anderson SD, Gonda I, Eberl S, Meikle S, Seale JP, Bautovich G. Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. Eur Respir J. 1996;9:725–732. doi: 10.1183/09031936.96.09040725.
    1. Feng W, Nakamura S, Sudo E, Lee MM, Shao A, King M. Effects of dextran on tracheal mucociliary velocity in dogs in vivo. Pulm Pharmacol Ther. 1999;12:35–41. doi: 10.1006/pupt.1999.0166.
    1. O'Callaghan C, Milner AD, Webb MS, Swarbrick A. Nebulised water as a bronchoconstricting challenge in infancy. Arch Dis Child. 1991;66:948–951.
    1. Barker R, Levison H. Effects of ultrasonically nebulized distilled water on airway dynamics in children with cystic fibrosis and asthma. J Pediatr. 1972;80:396–400.
    1. Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. Br Med J (Clin Res Ed) 1981;283:1285–1287.
    1. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med. 1999;159:1843–1848.
    1. Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson SD, Bye PT. The effect of inhaled mannitol on bronchial mucusclearancein cystic fibrosis patients: a pilot study. Eur Respir J. 1999;14:678–685. doi: 10.1034/j.1399-3003.1999.14c30.x.
    1. Kline JN, Waaldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, Thorne PS, Krieg AM. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol. 1998;160:2555–2559.
    1. Jain VV, Businga TR, Kitagaki K, George CL, O'Shaughnessy PT, Kline JN. Mucosal Immunotherapy with CpG Oligodeoxynucleotides Reverses a Murine Model of Chronic Asthma Induced by Repeated Antigen Exposure. Am J Physiol Lung Cell Mol Phsyiol. 2003;285:L1137–L1146.
    1. Noseda A, Schmerber J, Prigogine T, Yernault JC. Perceived effect on shortness of breath of an acute inhalation of saline or terbutalline: variability and sensitivity of a visual analogue scale in patients with asthma or COPD. Eur Respir J. 1992;5:1043–1053.
    1. Bijl-Hofland ID, Cloossterman SG, van Schayck CP, v d Elshout FJ, Akkermans RP, Folgering HT. Perception of respiratory sensation assessed by means of histamine challenge and threshold loading tests. Chest. 2000;117:954–959. doi: 10.1378/chest.117.4.954.
    1. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey BW. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized tobramycin study group. Chest. 1997;111:955–962.
    1. Standardization of spirometry. American Thoracic Society. 1994;143:1215–1223.
    1. Workshop summary and guidelines: investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airway diseases. J Allergy Clin Immunol. 1991;88:808–814.
    1. Singh PK, Tack BF, McCray P. B. Jr., Welsh MJ. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physlol. 2000;279:L799–L805.
    1. White SH, Wimley WC, Selsted ME. Structure, function, and membrane integration of defensins. Curr Opin Struct Biol. 1995;5:521–527. doi: 10.1016/0959-440X(95)80038-7.
    1. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol. 2002;14:96–102. doi: 10.1016/S0952-7915(01)00303-X.
    1. Forster H, Boecker S, Walther A. Use of xylitol as sugar substitute in diabetic children. Fortschr Med. 1977;95:99–102.
    1. Hauschildt S, Chalmers RA, Lawson AM, Schultis K, Watts RW. Metabolic investigations after xylitol infusion in human subjects. Am J Clin Nutr. 1976;29:258–273.
    1. Huttunen JK. Serum lipids, uric acid and glucose during chronic consumption of fructose and xylitol in healthy human subjects. Int Z Vitam Ernahrungsforsch Beih. 1976;15:105–115.
    1. Leutenegger AF, Goschke H, Stutz K, Mannhart H, Werdenberg J, Werdenberg D, Wolff G, Allgower M. Comparison between glucose and a combination of glucose, fructose, and xylitol as carbohydrates for total parenteral nutrition of surgical intensive care patients. Am J Surg. 1977;133:199–205. doi: 10.1016/0002-9610(77)90080-0.
    1. Conyers RA, Huber TW, Thomas DW, Rofe AM, Bais R, Edwards RG. A one-compartment model for calcium oxalate tissue deposition during xylitol infusions in humans. Int J Vitam Nutr Res Suppl. 1985;28:47–57.
    1. Conyers RA, Rofe AM, Bais R, James HM, Edwards JB, Thomas DW, Edwards RG. The metabolic production of oxalate from xylitol. Int J Vitam Nutr Res Suppl. 1985;28:9–28.
    1. Leidig P, Gerding W, Arns W, Ortmann M. Renal oxalosis with renal failure after infusion of xylitol. Dtsch Med Wochenschr. 2001;126:1357–1360. doi: 10.1055/s-2001-18650.
    1. Mercer RR, Russell ML, Roggli VL, Crapo JD. Cell number and distribution in human and rat airways. Am J Respir Cell Mol Biol. 1994;10:613–624.
    1. Wong BA, Tewksbury EW, Kelly JT, Asgharian B. Regional and lobar deposition of fine and coarse particles in the lungs of rats and mice. Toxicol Sci. 2003;72:39.
    1. Hantos Z, Brusasco V. Assessment of respiratory mechanics in small animals: the simpler the better? J Appl Physiol. 2002;93:1196–1197.
    1. Mitzner W, Tankersley C. Interpreting Penh in mice. J Appl Physiol. 2003;94:828–831.
    1. Kline JN. Effects of CpG DNA on Th1/Th2 balance in asthma. Curr Top Microbiol Immunol. 2000;247:211–225.
    1. Kline JN, Kitagaki K, Businga TR, Jain VV. Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physlol. 2002;283:L170–L179.
    1. McGowan SE, Smith J, Holmes AJ, Smith LA, Businga TR, Madsen MT, Kopp UC, Kline JN. Vitamin A deficiency promotes bronchial hyperreactivity in rats by altering muscarinic M(2) receptor function. Am J Physiol Lung Cell Mol Phsyiol. 2002;282:L1031–1039.

Source: PubMed

3
구독하다